Amyloid β-degrading cryptidases: Insulin degrading enzyme, presequence peptidase, and neprilysin

Cellular and Molecular Life Sciences

Volumn 65, Issue 16, 2008, Pages 2574-2585

  Malito, E ^a   Hulse, R E ^b   Tang, W J ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Alzheimer's disease; Amyloid peptide; Anti amyloidogenic therapy; Insulin degrading enzyme; Metalloprotease; Neprilysin; Presequence peptidase; X ray crystallography

Indexed keywords

AMYLOID BETA PROTEIN; INSULINASE; MEMBRANE METALLOENDOPEPTIDASE; PEPTIDASE; PROTEIN PRESEQUENCE PEPTIDASE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CHEMICAL INTERACTION; CONFORMATIONAL TRANSITION; ENCAPSULATION; ENZYME ACTIVE SITE; ENZYME REGULATION; ENZYME SPECIFICITY; ENZYME STRUCTURE; ENZYME SUBSTRATE; GENE THERAPY; HUMAN; IMMUNOTHERAPY; INSULIN DEGRADATION; MITOCHONDRION; NONHUMAN; REVIEW;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID BETA-PROTEIN; ANIMALS; HUMANS; INSULYSIN; MOLECULAR SEQUENCE DATA; NEPRILYSIN; PROTEIN PROCESSING, POST-TRANSLATIONAL; SUBSTRATE SPECIFICITY;

EID: 50249143450     PISSN: 1420682X     EISSN: 15691632     Source Type: Journal    
DOI: 10.1007/s00018-008-8112-4     Document Type: Review

References (102)

1. Puente, X. S., Sanchez, L. M., Overall, C. M. and Lopez-Otin, C. (2003) Human and mouse proteases: a comparative genomic approach. Nat. Rev. Genet. 4, 544-558.
2. Barrett, A. J. (2004) Handbook of proteolytic enzymes, Elsevier Academic Press, London ; San Diego.
3. Im, H., Manolopoulou, M., Malito, E., Shen, Y., Zhao, J., Neant-Fery, M., Sun, C. Y., Meredith, S. C., Sisodia, S. S., Leissring, M. A. and Tang, W. J. (2007) Structure of substrate-free human insulin-degrading enzyme (IDE) and biophysical analysis of ATP-induced conformational switch of IDE. J. - Biol. Chem. 282, 25453-25463.
4. Johnson, K. A., Bhushan, S., Stahl, A., Hallberg, B. M., Frohn, A., Glaser, E. and Eneqvist, T. (2006) The closed structure of presequence protease PreP forms a unique 10,000 Angstroms3 chamber for proteolysis. Embo J. 25, 1977-1986.
5. Oefner, C., D'Arcy, A., Hennig, M., Winkler, F. K. and Dale, G. E. (2000) Structure of human neutral endopeptidase (Neprilysin) complexed with phosphoramidon. J. Mol. Biol. 296, 341-349.
6. Oefner, C., Pierau, S., Schulz, H. and Dale, G. E. (2007) Structural studies of a bifunctional inhibitor of neprilysin and DPP-IV. Acta Crystallogr. D. Biol. Crystallogr. 63, 975-981.
7. Oefner, C., Roques, B. P., Fournie-Zaluski, M. C. and Dale, G. E. (2004) Structural analysis of neprilysin with various specific and potent inhibitors. Acta Crystallogr. D. Biol.. Crystallogr. 60, 392-396.
8. Shen, Y., Joachimiak, A., Rosner, M. R. and Tang, W.-J. (2006) Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism. Nature 443, 870-874.
9. Hartmann-Petersen, R. and Gordon, C. (2004) Proteins interacting with the 26S proteasome. Cell. Mol. Life Sci. 61, 1589-1595.
10. Smalle, J. and Vierstra, R. D. (2004) The ubiquitin 26S proteasome proteolytic pathway. Annu. Rev. Plant Biol. 55, 555-590.
11. Clausen, T., Southan, C. and Ehrmann, M. (2002) The HtrA family of proteases: implications for protein composition and cell fate. Mol. Cell 10, 443-455.
12. Kim, D. Y. and Kim, K. K. (2005) Structure and function of HtrA family proteins, the key players in protein quality control. J. Biochem. Mol. Biol. 38, 266-274.
13. Falkevall, A., Alikhani, N., Bhushan, S., Pavlov, P. F., Busch, K., Johnson, K. A., Eneqvist, T., Tjernberg, L., Ankarcrona, M. and Glaser, E. (2006) Degradation of the amyloid betaprotein by the novel mitochondrial peptidasome, PreP. J. Biol. Chem. 281, 29096-29104.
14. Kurochkin, I. V. (2001) Insulin-degrading enzyme: embarking on amyloid destruction. Trends Biochem. Sci. 26, 421-425.
15. Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E. A., Frosch, M. P., Eckman, C. B., Tanzi, R. E., Selkoe, D. J. and Guenette, S. (2003) Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. U. S. A. 100, 4162-4167.
16. Leissring, M. A., Farris, W., Chang, A. Y., Walsh, D. M., Wu, X., Sun, X., Frosch, M. P. and Selkoe, D. J. (2003) Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40, 1087-1093.
17. Eckman, E. A., Watson, M., Marlow, L., Sambamurti, K. and Eckman, C. B. (2003) Alzheimer's disease beta-amyloid peptide is increased in mice deficient in endothelin-converting enzyme. J. Biol. Chem. 278, 2081-2084.
18. Hemming, M. L., Patterson, M., Reske-Nielsen, C., Lin, L., Isacson, O. and Selkoe, D. J. (2007) Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease. P.L.o.S. Med. 4, e262.
19. Iwata, N., Tsubuki, S., Takaki, Y., Shirotani, K., Lu, B., Gerard, N. P., Gerard, C., Hama, E., Lee, H. J. and Saido, T. C. (2001) Metabolic regulation of brain Abeta by neprilysin. Science 292, 1550-1552.
20. Hamaguchi, T., Ono, K. and Yamada, M. (2006) Anti-amyloidogenic therapies: strategies for prevention and treatment of Alzheimer's disease. Cell. Mol. Life Sci. 63, 1538-1552.
21. Selkoe, D. J. (2001) Clearing the brain's amyloid cobwebs. Neuron 32, 177-180.
22. Tanzi, R. E., Moir, R. D. and Wagner, S. L. (2004) Clearance of Alzheimer's Abeta peptide: the many roads to perdition. Neuron 43, 605-608.
23. Turner, A. J. and Nalivaeva, N. N. (2007) New insights into the roles of metalloproteinases in neurodegeneration and neuroprotection. Int. Rev. Neurobiol. 82, 113-135.
24. Broh-Kahn, R. H. and Mirsky, I. A. (1949) The inactivation of insulin by tissue extracts; the effect of fasting on the insulinase content of rat liver. Arch. Biochem. 20, 10-14.
25. Mirsky, I. A., Perisutti, G. and Diengott, D. (1955) Effect of insulinase-inhibitor on destruction of insulin by intact mouse. Proc. Soc. Exp. Biol. Med. 88, 76-78.
26. Affholter, J. A., Fried, V. A. and Roth, R. A. (1988) Human insulin-degrading enzyme shares structural and functional homologies with E. coli protease III. Science 242, 1415-1418.
27. Rawlings, N. D., Morton, F. R. and Barrett, A. J. (2006) MEROPS: the peptidase database. Nucleic Acids Res. 34, D270-272.
28. Farris, W., Leissring, M. A., Hemming, M. L., Chang, A. Y. and Selkoe, D. J. (2005) Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein. Biochemistry 44, 6513-6525.
29. Leissring, M. A., Farris, W., Wu, X., Christodoulou, D. C., Haigis, M. C., Guarente, L. and Selkoe, D. J. (2004) Alternative translation initiation generates a novel isoform of insulin-degrading enzyme targeted to mitochondria. Biochem. J 383, 439-446.
30. Sladek, R., Rocheleau, G., Rung, J., Dina, C., Shen, L., Serre, D., Boutin, P., Vincent, D., Belisle, A., Hadjadj, S., Balkau, B., Heude, B., Charpentier, G., Hudson, T. J., Montpetit, A., Pshezhetsky, A. V., Prentki, M., Posner, B. I., Balding, D. J., Meyre, D., Polychronakos, C. and Froguel, P. (2007) A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445, 881-885.
31. Kurochkin, I. V. and Goto, S. (1994) Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. F.E.B.S. Lett. 345, 33-37.
32. Farris, W., Mansourian, S., Leissring, M. A., Eckman, E. A., Bertram, L., Eckman, C. B., Tanzi, R. E. and Selkoe, D. J. (2004) Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. Am. J. Pathol. 164, 1425-1434.
33. Miller, B. C., Eckman, E. A., Sambamurti, K., Dobbs, N., Chow, K. M., Eckman, C. B., Hersh, L. B. and Thiele, D. L. (2003) Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo. Proc. Natl. Acad. Sci. U. S. A. 100, 6221-6226.
34. Duckworth, W. C., Bennett, R. G. and Hamel, F. G. (1998) Insulin degradation: progress and potential. Endocr. Rev. 19, 608-624.
35. Qiu, W. Q. and Folstein, M. F. (2006) Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. Neurobiol. Aging 27, 190-198.
36. Misbin, R. I., Almira, E. C., Duckworth, W. C. and Mehl, T. D. (1983) Inhibition of insulin degradation by insulin-like growth factors. Endocrinology 113, 1525-1527.
37. Muller, D., Baumeister, H., Buck, F. and Richter, D. (1991) Atrial natriuretic peptide (ANP) is a high-affinity substrate for rat insulin-degrading enzyme. Eur. J. Biochem. 202, 285-292.
38. Muller, D., Schulze, C., Baumeister, H., Buck, F. and Richter, D. (1992) Rat insulin-degrading enzyme: cleavage pattern of the natriuretic peptide hormones ANP, BNP, and CNP revealed by HPLC and mass spectrometry. Biochemistry 31, 11138-11143.
39. Roth, R. A., Mesirow, M. L., Yokono, K. and Baba, S. (1984) Degradation of insulin-like growth factors I and II by a human insulin degrading enzyme. Endocr. Res. 10, 101-112.
40. Bennett, R. G., Duckworth, W. C. and Hamel, F. G. (2000) Degradation of amylin by insulin-degrading enzyme. J. Biol. Chem. 275, 36621-36625.
41. Kurochkin, I. V. (1998) Amyloidogenic determinant as a substrate recognition motif of insulin-degrading enzyme. F.E.B.S. Lett. 427, 153-156.
42. Taubes, G. (2003) Neuroscience. Insulin insults may spur Alzheimer's disease. Science 301, 40-41.
43. Watson, G. S., Peskind, E. R., Asthana, S., Purganan, K., Wait, C., Chapman, D., Schwartz, M. W., Plymate, S. and Craft, S. (2003) Insulin increases CSF Abeta42 levels in normal older adults. Neurology 60, 1899-1903.
44. Hooper, N. M. (1994) Families of zinc metalloproteases. F.E.B.S. Lett. 354, 1-6.
45. Maskos, K. (2004) Pitrilysins/inverzincins. In Handbook of metalloproteins (Messerschmidt, A., Dode, W. and Cygler, M., eds) Vol. 3 pp. 190-198, John Wiley & Sons
46. Taylor, A. B., Smith, B. S., Kitada, S., Kojima, K., Miyaura, H., Otwinowski, Z., Ito, A. and Deisenhofer, J. (2001) Crystal structures of mitochondrial processing peptidase reveal the mode for specific cleavage of import signal sequences. Structure 9, 615-625.
47. Li, P., Kuo, W. L., Yousef, M., Rosner, M. R. and Tang, W. J. (2006) The C-terminal domain of human insulin degrading enzyme is required for dimerization and substrate recognition. Biochem. Biophys. Res. Commun. 343, 1032-1037.
48. Leissring, M. A. and Selkoe, D. J. (2006) Structural biology: enzyme target to latch on to. Nature 443, 761-762.
49. Mzhavia, N., Berman, Y. L., Qian, Y., Yan, L. and Devi, L. A. (1999) Cloning, expression, and characterization of human metalloprotease 1: a novel member of the pitrilysin family of metalloendoproteases. DNA Cell Biol. 18, 369-380.
50. Moberg, P., Stahl, A., Bhushan, S., Wright, S. J., Eriksson, A., Bruce, B. D. and Glaser, E. (2003) Characterization of a novel zinc metalloprotease involved in degrading targeting peptides in mitochondria and chloroplasts. Plant J. 36, 616-628.
51. Stahl, A., Moberg, P., Ytterberg, J., Panfilov, O., Brockenhuus Von Lowenhielm, H., Nilsson, F. and Glaser, E. (2002) Isolation and identification of a novel mitochondrial metalloprotease (PreP) that degrades targeting presequences in plants. J. Biol. Chem. 277, 41931-41939.
52. Caspersen, C., Wang, N., Yao, J., Sosunov, A., Chen, X., Lustbader, J. W., Xu, H. W., Stern, D., McKhann, G. and Yan, S. D. (2005) Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. Faseb J. 19, 2040-2041.
53. Lustbader, J. W., Cirilli, M., Lin, C., Xu, H. W., Takuma, K., Wang, N., Caspersen, C., Chen, X., Pollak, S., Chaney, M., Trinchese, F., Liu, S., Gunn-Moore, F., Lue, L. F., Walker, D. G., Kuppusamy, P., Zewier, Z. L., Arancio, O., Stern, D., Yan, S. S. and Wu, H. (2004) ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 304, 448-452.
54. Roques, B. P., Noble, F., Dauge, V., Fournie-Zaluski, M. C. and Beaumont, A. (1993) Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol. Rev. 45, 87-146.
55. Turner, A. J. and Tanzawa, K. (1997) Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. Faseb J. 11, 355-364.
56. Bur, D., Dale, G. E. and Oefner, C. (2001) A three-dimensional model of endothelin-converting enzyme (ECE) based on the X-ray structure of neutral endopeptidase 24.11 (NEP). Protein Eng. 14, 337-341.
57. Eckman, E. A., Adams, S. K., Troendle, F. J., Stodola, B. A., Kahn, M. A., Fauq, A. H., Xiao, H. D., Bernstein, K. E. and Eckman, C. B. (2006) Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme. J. Biol. Chem. 281, 30471-30478.
58. Eckman, E. A., Reed, D. K. and Eckman, C. B. (2001) Degradation of the Alzheimer's amyloid beta peptide by endothelin-converting enzyme. J. Biol. Chem. 276, 24540-24548.
59. Iwata, N., Tsubuki, S., Takaki, Y., Watanabe, K., Sekiguchi, M., Hosoki, E., Kawashima-Morishima, M., Lee, H. J., Hama, E., Sekine-Aizawa, Y. and Saido, T. C. (2000) Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat. Med. 6, 143-150.
60. Shirotani, K., Tsubuki, S., Iwata, N., Takaki, Y., Harigaya, W., Maruyama, K., Kiryu-Seo, S., Kiyama, H., Iwata, H., Tomita, T., Iwatsubo, T. and Saido, T. C. (2001) Neprilysin degrades both amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases. J. Biol. Chem. 276, 21895-21901.
61. Iwata, N., Takaki, Y., Fukami, S., Tsubuki, S. and Saido, T. C. (2002) Region-specific reduction of A beta-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. J. Neurosci. Res. 70, 493-500.
62. Russo, R., Borghi, R., Markesbery, W., Tabaton, M. and Piccini, A. (2005) Neprylisin decreases uniformly in Alzheimer's disease and in normal aging. F.E.B.S. Lett. 579, 6027-6030.
63. Yasojima, K., Akiyama, H., McGeer, E. G. and McGeer, P. L. (2001) Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide. Neurosci. Lett. 297, 97-100.
64. Yasojima, K., McGeer, E. G. and McGeer, P. L. (2001) Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain. Brain Res. 919, 115-121.
65. Marr, R. A., Rockenstein, E., Mukherjee, A., Kindy, M. S., Hersh, L. B., Gage, F. H., Verma, I. M. and Masliah, E. (2003) Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J. Neurosci. 23, 1992-1996.
66. Mohajeri, M. H., Wollmer, M. A. and Nitsch, R. M. (2002) Abeta 42-induced increase in neprilysin is associated with prevention of amyloid plaque formation in vivo. J. Biol. Chem. 277, 35460-35465.
67. Yanagisawa, H., Yanagisawa, M., Kapur, R. P., Richardson, J. A., Williams, S. C., Clouthier, D. E., de Wit, D., Emoto, N. and Hammer, R. E. (1998) Dual genetic pathways of endothelin-mediated intercellular signaling revealed by targeted disruption of endothelin converting enzyme-1 gene. Development 125, 825-836.
68. Iwase, A., Shen, R., Navarro, D. and Nanus, D. M. (2004) Direct binding of neutral endopeptidase 24.11 to ezrin/ radixin/moesin (ERM) proteins competes with the interaction of CD44 with ERM proteins. J. Biol. Chem. 279, 11898-11905.
69. Terawaki, S., Kitano, K. and Hakoshima, T. (2007) Structural basis for type II membrane protein binding by ERM proteins revealed by the radixin-neutral endopeptidase 24.11 (NEP) complex. J. Biol. Chem. 282, 19854-19862.
70. Wade, R. C., Gabdoulline, R. R., Ludemann, S. K. and Lounnas, V. (1998) Electrostatic steering and ionic tethering in enzyme-ligand binding: insights from simulations. Proc. Natl. Acad. Sci. U. S. A. 95, 5942-5949.
71. Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E. and Holtzman, D. M. (2006) Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat. Med. 12, 856-861.
72. DeMattos, R. B., Bales, K. R., Cummins, D. J., Paul, S. M. and Holtzman, D. M. (2002) Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295, 2264-2267.
73. Tanzi, R. E. and Bertram, L. (2005) Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120, 545-555.
74. Qiu, W. Q., Walsh, D. M., Ye, Z., Vekrellis, K., Zhang, J., Podlisny, M. B., Rosner, M. R., Safavi, A., Hersh, L. B. and Selkoe, D. J. (1998) Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J. Biol. Chem. 273, 32730-32738.
75. Vekrellis, K., Ye, Z., Qiu, W. Q., Walsh, D., Hartley, D., Chesneau, V., Rosner, M. R. and Selkoe, D. J. (2000) Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J. Neurosci. 20, 1657-1665.
76. Mentlein, R., Ludwig, R. and Martensen, I. (1998) Proteolytic degradation of Alzheimer's disease amyloid beta-peptide by a metalloproteinase from microglia cells. J. Neurochem. 70, 721-726.
77. Sudoh, S., Frosch, M. P. and Wolf, B. A. (2002) Differential effects of proteases involved in intracellular degradation of amyloid beta-protein between detergent-soluble and -insoluble pools in CHO-695 cells. Biochemistry 41, 1091-1099.
78. Li, Q., Ali, M. A. and Cohen, J. I. (2006) Insulin degrading enzyme is a cellular receptor mediating varicella-zoster virus infection and cell-to-cell spread. Cell 127, 305-316.
79. Stahl, A., Nilsson, S., Lundberg, P., Bhushan, S., Biverstahl, H., Moberg, P., Morisset, M., Vener, A., Maler, L., Langel, U. and Glaser, E. (2005) Two novel targeting peptide degrading proteases, PrePs, in mitochondria and chloroplasts, so similar and still different. J. Mol. Biol. 349, 847-860.
80. Emoto, N., Nurhantari, Y., Alimsardjono, H., Xie, J., Yamada, T., Yanagisawa, M. and Matsuo, M. (1999) Constitutive lysosomal targeting and degradation of bovine endothelin-converting enzyme-1a mediated by novel signals in its alternatively spliced cytoplasmic tail. J. Biol. Chem. 274, 1509-1518.
81. Mzhavia, N., Pan, H., Che, F. Y., Fricker, L. D. and Devi, L. A. (2003) Characterization of endothelin-converting enzyme-2. Implication for a role in the nonclassical processing of regulatory peptides. J. Biol. Chem. 278, 14704-14711.
82. Pearson, H. A. and Peers, C. (2006) Physiological roles for amyloid beta peptides. J. Physiol. 575, 5-10.
83. Young-Pearse, T. L., Bai, J., Chang, R., Zheng, J. B., LoTurco, J. J. and Selkoe, D. J. (2007) A critical function for beta-amyloid precursor protein in neuronal migration revealed by in utero RNA interference. J. Neurosci. 27, 14459-14469.
84. Meyer-Luehmann, M., Spires-Jones, T. L., Prada, C., Garcia-Alloza, M., de Calignon, A., Rozkalne, A., Koenigsknecht-Talboo, J., Holtzman, D. M., Bacskai, B. J. and Hyman, B. T. (2008) Rapid appearance and local toxicity of amyloid-beta plaques in amouse model of Alzheimer's disease. Nature 451, 720-724.
85. Bacskai, B. J., Kajdasz, S. T., Christie, R. H., Carter, C., Games, D., Seubert, P., Schenk, D. and Hyman, B. T. (2001) Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med. 7, 369-372.
86. Bacskai, B. J., Kajdasz, S. T., McLellan, M. E., Games, D., Seubert, P., Schenk, D. and Hyman, B. T. (2002) Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J. Neurosci. 22, 7873-7878.
87. Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., Mount, H. T., Nixon, R. A., Mercken, M., Bergeron, C., Fraser, P. E., St George-Hyslop, P. and Westaway, D. (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979-982.
88. Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C., Hardy, J., Duff, K., Jantzen, P., DiCarlo, G., Wilcock, D., Connor, K., Hatcher, J., Hope, C., Gordon, M. and Arendash, G. W. (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982-985.
89. Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., Kholodenko, D., Lee, M., Liao, Z., Lieberburg, I., Motter, R., Mutter, L., Soriano, F., Shopp, G., Vasquez, N., Vandevert, C., Walker, S., Wogulis, M., Yednock, T., Games, D. and Seubert, P. (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177.
90. Akiyama, H. and McGeer, P. L. (2004) Specificity of mechanisms for plaque removal after A beta immunotherapy for Alzheimer disease. Nat. Med. 10, 117-118; author reply 118-119.
91. Nicoll, J. A., Wilkinson, D., Holmes, C., Steart, P., Markham, H. and Weller, R. O. (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9, 448-452.
92. Kleywegt, G. J. and Jones, T. A. (1994) Detection, delineation, measurement and display of cavities in macromolecular structures. Acta. Crystallogr. D. Biol. Crystallogr. 50, 178-185.
93. Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M.,Meng, E. C. and Ferrin, T. E. (2004) UCSF Chimera-a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605-1612.
94. Bentley, G., Dodson, E., Dodson, G., Hodgkin, D. and Mercola, D. (1976) Structure of insulin in 4-zinc insulin. Nature 261, 166-168.
95. Torres, A. M., Forbes, B. E., Aplin, S. E., Wallace, J. C., Francis, G. L. and Norton, R. S. (1995) Solution structure of human insulin-like growth factor II. Relationship to receptor and binding protein interactions. J. Mol. Biol. 248, 385-401.
96. Cooke, R. M., Harvey, T. S. and Campbell, I. D. (1991) Solution structure of human insulin-like growth factor 1: a nuclear magnetic resonance and restrained molecular dynamics study. Biochemistry 30, 5484-5491.
97. Sticht, H., Bayer, P., Willbold, D., Dames, S., Hilbich, C., Beyreuther, K., Frank, R. W. and Rosch, P. (1995) Structure of amyloid A4-(1-40)-peptide of Alzheimer's disease. Eur. J. Biochem. 233, 293-298.
98. Fairbrother, W. J., McDowell, R. S. and Cunningham, B. C. (1994) Solution conformation of an atrial natriuretic peptide variant selective for the type A receptor. Biochemistry 33, 8897-8904.
99. He, X. L., Dukkipati, A. and Garcia, K. C. (2006) Structural determinants of natriuretic peptide receptor specificity and degeneracy. J. Mol. Biol. 361, 698-714.
100. Chesneau, V. and Rosner, M. R. (2000) Functional human insulin-degrading enzyme can be expressed in bacteria. Protein Expr. Purif. 19, 91-98.
101. Misbin, R. I. and Almira, E. C. (1989) Degradation of insulin and insulin-like growth factors by enzyme purified from human erythrocytes. Comparison of degradation products observed with A14- and B26-[125I] monoiodoinsulin. Diabetes 38, 152-158.
102. DeLano, W. (2002) The PyMOL Molecular Graphics System. DeLano Scientific, Palo Alto, CA, USA.